Dear Colleagues,

It is a great pleasure to announce the opening of a section collection dedicated to Nanomedicine and Tumor Immunotherapy. The aim of this section is to focus on publications on the cancer immunotherapy through various nanomaterials-based drug delivery systems and/or nanomedicine forms. All published studies are subject to peer review prior to acceptance by the editors of this Section and must meet the ethical and peer-review standards set by the journal. We intend to broadly cover basic research on those nanomedicine-based therapeutics as well as translational research, ranging from the design and preclinical to clinical development. A special focus will be on novel oncology treatments and immunotherapeutic with a novel mechanism of action, bridging basic and translational research. It is an explicit desire to broaden the field of the development of nanomedicine for tumor immunotherapy. Indeed, immunoregulatory therapies against non-commutable diseases such as chronic inflammation and cancer mediated by functional nanomaterials are explicitly areas of interest. Original research papers and review articles are welcomed.

We look forward to receiving your contributions.
Dr. Liangliang Dai

Prof. Dr. Luciano Mutti

Dr. Ghasem Ghalamfarsa
Dr. Juliana Aparecida Preto de Godoy

Dr. Nikhil Agrawal

Dr. Bing Xia

Dr. Katarzyna Kotwica-Mojzych

Prof. Zhixin Zhang

Dr. Sedigheh Taghinezhadsaroukalaei

Dr. Yan Wang

Prof. Dr. Owais Mohammad

Dr Ahmad Sufian Ab Rahman

Section Editors